# Curriculum Vitae di Sara Gandini

Sara Gandini, PhD Director, Molecular and Pharmaco-Epidemiology Unit European Institute of Oncology

## Academic information

2017 National Academic Qualification as Associate Professor (medical statistics)

2004 PHD IN CANCER STUDIES at the University of Birmingham (Public Health), UK. Thesis: "Meta-Analysis in Cancer Epidemiology".

1995 MASTER OF SCIENCE IN BIOMETRY at the Department of Applied Statistics at the University of Reading (UK). Thesis in Epidemiology: "Ordered categorical modelling of categorical data from the Scottish Heart Health Study".

1993 Doctor in STATISTICS at the University of Bologna, with the score 110/110 WITH HONOURS (first class degree). "Corso di laurea in Scienze statistiche ed economiche". Thesis in statistical methods: "Choice of logistic models".

H-index=44 (SCOPUS May 2018). More than 160 publications in peer reviews journals. Total number of publications as first or last name or corresponding author=60.

Orcid: 0000-0002-1348-4548 Research id: J-4916-2018

## Positions

Since 2018 Tenure group Leader. Director of "Molecular and Pharmaco-Epidemiology" unit at the department of Experimental oncology (Istituto Europeo di Oncologia -IEO)

Since 2016 Adjunct professor in medical statistic at University "Statale di Milano"

Since 2009 Employed as Senior Staff Scientist at the division of Epidemiology and Biostatistics Division in IEO, Milan (Italy).

Since 2014 Statistical consultant at Multimedica Ethics committee, Milan, Italy.

Since 2014 Member of EORTC Steering committee of the Melanoma group and Chair of the Melanoma Epi-subgroup.

2002-2009 Employed as Staff Scientist in Epidemiology and Biostatistics Division at IEO, Milan (Italy).

1997-2002 Employed as Scientist in Epidemiology and Biostatistics Division at the European Institute of IEO, Milan (Italy).

1996 Fellow at the Division of Epidemiology and Biostatistics of IEO.

1993-1994 Teacher of Mathematics in high school in Italy.

### Member of Data Safety Monitor Board of multicentre clinical trials

-A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in stage IIII colorectal cancer patients. The ASAMET Trial (start in 2015)

-Italian phase III clinical Trial of Low Dose Tamoxifen in Women with Breast Intraepithelial Neoplasia (start in 2013)

-Clinical trial organized by Novartis Vaccines in India and Pakistan (start in 2010)

### Lecturer

2015-2016 Lecturer at Master in Epidemiology (Department of MEDICINA CLINICA E SPERIMENTALE), University of Parma, Italy.

2015 Lecturer at Master Course in "Applied research" organized by University of Milan ("Dipartimento di Scienze della Salute & Centro di Ricerca e Intervento sui Processi Decisionali") in collaboration with the European Institute of Oncology (IEO).

2014 Lecturer at 'The European School of Oncology (ESO)' in Romania. Member of European School of Oncology faculty core

2009-2014 Statistical methods course in medical research at IEO. Grants as PI

2014 Associazione Italiana per la Ricerca sul Cancro (AIRC): Principal investigator of a project about Vitamin D on microbiome in colorectal cancer: Pilot trial

2013 Fondazione Umberto Veronesi (FUV): Principal investigator of a project about Vitamin D on microbiome in colorectal cancer: case-control study

2010 Fondazione Umberto Veronesi (FUV): Principal investigator of a project on "Biomarkers studies on stage II melanoma patients treated with Vitamin D".

#### Grants as collaborator

2015 National Cancer Institute: "Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial". Protocol Lead Organization: MD Anderson, in collaboration with Division of Cancer Prevention and Genetics (IEO)

2015 Health Italian Ministry (Bando Ricerca Finalizzata): "Low adiponectin levels as independent risk marker for breast cancer in high risk postmenopausal women"; in collaboration with Division of Cancer Prevention and Genetics (IEO).

2015 "Ricerca Scientifica dell'Ente Ospedaliero Cantonale (ABREOC)": Multicentre study to evaluate the effect of counselling for breast cancer patients facing treatment or screening decisions.

2014 ERA-NET on Translational Cancer Research (TRANSCAN): "A phase II study with metformin in breast cancer survivors at higher risk for recurrence" in collaboration with Division of Cancer Prevention and Genetics (IEO)"

2013 Regione Toscana: "MelaBlock: Randomized clinical trial for melanoma stage II patients to assess effect of  $\beta$ -adrenoceptor blockers on melanoma recurrence" in collaboration with University of Florence.

2012 European Space Agency (ESA): Research Using Concordia Antarctic Station as Human Exploration Analogue (AO-11-Concordia). Team member for the project: "Impact of Vitamin D supplementation on health markers at Concordia (VITAD)"